A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

Официальное название

A Phase 2 Multi-center, Randomized, Open-Label, Dose Regimen-Finding Study of AGA2115 in Chinese Adults and Adolescents With Type I, III, or IV Osteogenesis Imperfecta

Обзор

This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).

Подробное описание

This Phase 2 study will evaluate the safety and efficacy of AGA2115 in three different dosing regimens in Chinese adults and adolescents with Type I, III, or IV OI. Participants will be in the study for 24 or 27 months depending on their assigned cohort. During the first 12 months of the study, adult and adolescent participants will be randomized separately in a 1:1:1:1 ratio to one of three AGA2115 dosing regimens or control cohort. During months 12 to 24 or 27, all participants will receive AGA2115 and attend visits for the evaluation of safety and efficacy parameters.

Вмешательства

• Препарат AGA2115
  Participants will receive AGA2115 administered by subcutaneous injection

Первичные конечные точки

• Occurrence of Treatment-Emergent Adverse Events (TEAEs) [Срок оценки: Baseline to Month 27 (Cohorts 1 and 5); Baseline to Month 24 (Cohorts 2, 3, 4, 6, 7 and 8)]

Вторичные конечные точки (7)

• Percent change from Baseline at Month 3, 6, 9 and 12 in Bone Mineral Density (BMD) at lumbar spine, total hip, femoral neck, one-third distal radius, and total body (minus head) for adults and adolescents. [Срок оценки: Months 3, 6, 9, and 12]
• Change from Baseline at Month 3, 6, 9, and 12 in BMD Z-score at lumbar spine, total hip, femoral neck, one-third distal radius, and total body (minus head) for adolescents. [Срок оценки: Month 3, 6, 9, and 12]
• Percent Change from Baseline at Week 1 and Month 1, 3, 6, 9, and 12 in bone turnover markers CTX-1 and P1NP [Срок оценки: Week 1, Month 1, 3, 6, 9, and 12]
• Percentage of participants with fractures between Baseline and Month 12 [Срок оценки: Baseline to Month 12]
• Annualized fracture rate for incident fractures occurring between Baseline and Month 12 [Срок оценки: Baseline to Month 12]
• AGA2115 observed concentration for the treatment groups [Срок оценки: Day 1 to Month 27 (Cohorts 1 and 5); Day 1 to Month 24 (Cohorts 2, 3, 4, 6, 7 and 8).]
• Serum anti-AGA2115 antibodies [Срок оценки: Day 1 to Month 27 (Cohorts 1 and 5); Day 1 to Month 24 (Cohorts 2, 3, 4, 6, 7 and 8).]

Критерии участия

Критерии включения

• Adults (18-75 years) or adolescents (12-17 years) with a confirmed diagnosis of Osteogenesis Imperfecta (OI) Type I, III, or IV with genetic confirmation of pathogenic variants in COL1A1 or COL1A2 genes
• BMD T-score of ≤-1.0 at the lumbar spine, total hip, or femoral neck (adults) or BMD Z-score of ≤-1.0 at the lumbar spine, total hip, or femoral neck (adolescents)
• Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol

Критерии исключения

• Vitamin D deficiency
• Concomitant uncontrolled diseases or conditions that could affect bone metabolism such as hypo-/hyperparathyroidism, hypo-/hyperthyroidism, abnormal thyroid function or thyroid disease, or other endocrine disorders.
• Current hyper- or hypocalcemia.
• History of rickets, osteomalacia, or other significant skeletal disorders (excluding OI) leading to long-bone deformities and/or increased risk of fractures.
• Use of bisphosphonates within the past 6 months.
• Use of teriparatide, abaloparatide, strontium ranelate, or hormone replacement therapy within the past 12 months.
• Use of denosumab (or denosumab biosimilars) within the past 2 years.
• Use of anti-sclerostin antibody medications (romosozumab, setrusumab, blosozumab) at any time.
• History of myocardial infarction or stroke (or other cardiovascular associated event deemed significant) within the past 12 months.
• Malignancy within the last 5 years.
• Pregnant or breastfeeding women, or women planning to become pregnant during the study or within 4 months after the last dose of IP.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 4 центра

• Chinese Academy of Medical Sciences, Peking Union Medical College Hospital — Пекин
• The University of Hong Kong-Shenzhen Hospital — Шэньчжэнь
• Children's Hospital of Soochow University — Сучжоу
• Shanghai Sixth People's Hospital — Шанхай

Идентификаторы

NCT: NCT07557446 · ACT24-003

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗